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Table 1
Impact of age at ﬁrst blood transfusion and total number of transfusions
prior to transplant on graft rejection.
Had graft
rejection
N (%) /
MeanSD/
Median
(Range)
Did not
have graft
rejection
N (%) /
MeanSD/
Median
(Range)
Cox
regression
Univariate
analysis
Cox
regression
Multivariate
analysis
N 48 341 P-value P-value
Age at ﬁrst
transfusion
(months)
10.513.4 7.76.7 0.036 0.022
Total number
of
transfusions
prior to SCT
100 (6-
373)
85 (4-450) NS
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inferior OS on univariate analysis were: relapse within 6
months, relapsewithin 12months, grade 3-4 acuteGVHDprior
to relapse, FLT3-ITD mutation, prior induction failure, marrow
blasts> 30% at relapse, use of a Tcell replete graft, and absence
of chronicGVHDprior to relapse. Onmultivariate analysis, only
relapsewithin 6months (HR 2.3, P< .001), and grade 3-4 acute
GVHD prior to relapse (HR 2.0, P¼ .004), remained signiﬁcant.
These two factors were combined into a prognostic index and
validated; in thevalidationcohort, patientswith1-2 factorshad
inferior OS compared to thosewith 0 factors (HR 2.5, P< .001).
This effect remained signiﬁcant when analysis was limited to
the validation cohort patients given salvage (HR 2.3, P ¼ .002).
Aim 2: Of 333 analysable patients, 134 patients were not given
salvage; theirmedian survivalwas33.5days.199patients given
salvage had 5y OS of 14%. First salvage therapy was second
alloHSCT (ie conditioning plus donor cell infusion) in 55; donor
lymphocyte infusion (DLI) (ie donor cell infusion without
conditioning) in 16; reinduction chemotherapy (CT) without
planned cell infusion in 75; radiotherapy in 8, interferon in 6,
and unknown in 7. We deﬁned donor cell therapy (DCT) as
second alloHSCT or DLI. Characteristics of patients receiving
DCT as ﬁrst salvage, and patients receiving CT as ﬁrst salvage,
were similar, although CT recipients had shorter median
follow-upof survivors (11.2 vs 36.7months, P¼ .017). CTasﬁrst
salvagewas inferior topatients receivingDCTasﬁrst salvage (5y
OS5%vs23%,HR1.8,P<.001). ForpatientsgivenDCTﬁrst, there
was no difference in OS between second alloHSCT and DLI (HR
1.1 for second alloHSCT, P ¼ .697). We were unable to demon-
strate a beneﬁt in OS for patients with post-relapse GVHD (HR
0.8 forpresenceofGVHD,P¼ .405).Ourﬁndingsunderscore the
poor prognosis of relapsed AML post alloHSCT and provide
useful baseline data for future interventional studies. Patients
with relapsebeyond6months fromalloHSCTandwithoutprior
grade 3-4 acute GVHD may expect better OS with salvage
compared to those with either or both factors. Overall, better
outcomes for OS were with DCT as initial treatment.26
Delay in Onset of First Transfusion and Increased Risk of
Graft Rejection in b Thalassemia Patients Undergoing a
HLA Matched Related Allogeneic Stem Cell Transplant
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Allogeneic stem cell transplant (SCT) remains the only cura-
tive option for patients with b thalassemia major (TM). Graft
rejection has been a major problem in this group of patients.
The increased risk of graft rejection has often been attributed
to the number of blood transfusions that these patients are
exposed to. However, the published data is confusing with
one large series suggesting that patients who had >100
transfusion pre-SCT had a signiﬁcantly lower risk of graft
rejection (Blood 1996; 87: 2082). It is also generally accepted
that in patients with thalassemia intermedia the risk
of alloimmunisation (red cell) is reduced if transfusion is
initiated <12 months of age (Vox Sang 1990; 58:50).
From October, 1991 to April, 2013, 400 HLA matched related
transplants forTMwasdoneatourcenter. Themedianagewas8
years (range: 1-24) and there were 250 (62.5%) males. 154
(38.5%) were Lucarelli Class II and 229 (57.2%) were in the Class
III risk group. Majority (72%) received a busulfan based condi-
tioning regimenwhile 22% received a treosulfanbased regimen.
Bonemarrowwasthesourceof stemcells in81%andPBSC inthe
rest. There were 11 (2.8%) early regimen related toxicity (RRT)deaths prior to day 12 and these were excluded for analysis of
graft rejection.Of theremaining389cases therewere48(12.3%)
graft rejections. Among these 26 (54%) were primary graft fail-
ures while 22 (46%) were secondary graft failures. The median
ageatﬁrst transfusion in this cohortwas6months (range:1-66;
data not available in 10). The median number of blood trans-
fusions prior to SCT was 85 (range: 4 e 450).
After excluding early RRT deaths the EFS and OS of the entire
cohort was 702.5% and 772.2% respectively. On a univar-
iate cox regression analysis the variables that impacted graft
rejection signiﬁcantly were donor age (P¼0.000), liver size
(P¼0.007) and increased age at ﬁrst blood transfusion
(P¼0.035). The total number of transfusions prior to SCT was
not signiﬁcantly associated with graft rejection (P¼0.894)
(Table 1). On a multivariate analysis only liver size (P¼0.019)
and age at ﬁrst transfusion (P¼0.022) retained their statis-
tically signiﬁcant adverse effect.
In conclusion, delay in the onsetof transfusion inpatientswith
b thalassemia major undergoing a HLA matched related allo-
geneic SCT probably has a greater adverse effect on engraft-
ment than the total number of transfusions prior to SCT.
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Background: GA predicts for mortality in older solid tumor
cancer patients but its prognostic value in allogeneic HCT has
not previously been reported.
Methods: Patients >¼50 years were eligible. GA was per-
formed within 1 month prior to HCT, and evaluated function
and disability, frailty, comorbidity, mental health, nutrition,
and inﬂammation with the following measures: ECOG per-
formance status (PS), Activities of Daily Living, Instrumental
Activities of Daily Living (IADL), SF-36 Physical Component
Summary, Fried Frailty Index (incorporates walk speed and
grip strength), HCT- Comorbidity Index (HCT-CI), Cumulative
Illness Rating Scale- Geriatrics, SF-36 Mental Component
Summary (SF36-MCS), serum albumin, self-reported weight
loss, and serum C-reactive protein (CRP). Survival curves were
generated using Kaplan-Meier method; log-rank test
compared groups. Multivariate models for 2-year overall sur-
vival (OS) incorporated each GA variable signiﬁcant at P <0.10
Table 1
Multivariate OS Analysis
Total Cohort HR
95% CI P
50-59 Years
HR 95% CI P
60-73 Years
HR 95% CI P
STANDARD
VARIABLES
Age >60 1.83 1.26-
2.65
.001
HCT-CI >¼3 1.56 1.07-
2.28
.02 1.50 .88-
2.53
.13 1.72 .99-
2.98
.05
Active Disease 1.31 .90-
1.90
.16 1.54 .92-
2.58
.10 1.27 .71-
2.27
.42
Ablative
Regimen
1.54 1.02-
2.31
.04 2.14 1.24-
3.69
.01 1.07 .54-
2.10
.85
GA VARIABLES
IADL
Impairment
2.38 1.59-
3.56
<.001 1.86 1.07-
3.24
.03 3.25 1.75-
6.05
<.001
Slow Walk
Speed
1.80 1.14-
2.83
.01 1.16 .60-
2.28
.66 3.27 1.68-
6.39
.001
Reduced
Mental
Health
1.67 1.13-
2.48
.01 1.55 .92-
2.62
.10 1.87 1.01-
3.49
.04
Low Albumin 1.52 .94-
2.46
.09 1.23 .57-
2.63
.60 2.62 1.26-
5.47
.01
High CRP 2.51 1.54-
4.09
<.001 1.89 .94-
3.79
.07 3.13 1.52-
6.46
.002
*Each GA measure analyzed separately, adjusting for standard variables
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(age, HCT-CI, conditioning regimen intensity, disease risk).
Results: 203 adults >¼50 years completed GA and under-
went HCT.Mean agewas 59 years (range 50-73); 45% had high
disease risk, 76% received reduced intensity conditioning, and
14% underwent cord blood HCT. With median follow-up of 36
months, IADL limitations (P < 0.0001), slow walk speed (P ¼
0.01), low SF36-MCS (P¼ 0.01), and high CRP (P<0.001) were
signiﬁcantly associated with inferior OS, independent of
standard HCT variables. The prognostic effect of these GA
variables was greater in older recipients (Table 1). We then
created a simple risk score with 1 point for the most prog-
nostic functional measure (IADL impairment) and 1 point for
comorbidity (HCT-CI >¼3). This signiﬁcantly stratiﬁed out-
comes, particularly in those 60 years, such that 2-year OS
was 63%, 29%, and 0% for 0, 1, and 2 points, respectively.
Conclusion: GA measures confer independent prognostic
utility in older HCT recipients, especially in those >¼60
years. Implementation of GA prior to HCT may aid in
appropriate selection of older adults for HCT.
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Background: Recent studies have shown the intravenous
administration of high-dose cyclophosphamide (CY) in the
early post-transplant period to be a strategy for GvHD
prophylaxis in patients with hematologic malignancies who
receive allogeneic marrow grafts from alternative donors.
We evaluated the outcomes of patients who received
HPC-Apheresis products to compare the impact of post-
transplant CY on neutrophil engraftment, hematopoietic
chimerism, and early immune reconstitution in patients who
received post-HSCT CY following haplo-identical (HAP),matched unrelated donor (MUD), andmismatched unrelated
donor (mMUD) grafts vs. with conventional matched related
donor (MRD) graft recipients.
Methods and Results: We transplanted 44 patients (median
age, 49 years; range, 20-72 years) with advanced hemato-
logic malignancies n¼8 (HAP); 14 (MRD); 17 (MUD); 5
(mMUD). All patients received conditioning regimens based
on busulfan or total body irradiation (TBI). High-dose CY
(50mg/kg/day) was administered on days 3 and 4 following
HAP and on day 3 following MUD transplant. Peripheral
blood lymphocyte reconstitution and quantitative T-cell and
myeloid speciﬁc donor chimerism (STR) status was assessed
on post-HSCT days 30 and 60. Mean time to ANC 500 was
12.5 days for MRD, mMUD and MUD graft recipients. HAP
recipients took slightly longer at 15.2 days but not signiﬁ-
cantly different from others. Day +30 median CD3/CD15
chimerism was 82.3+12.4/99.8+0.5 for MRD; 86.7+16.0/
97.6+2.2 for MUD; 87.6+15.3/99.8+0.4 for mMUD; and
98.8+1.8/99.2+1.2 for HAP. Day +30 HAP CD3 chimerism was
signiﬁcantly improved over MRD (p<0.001) but not over
MUD or mMUD. CD15 chimerism did not differ between
groups. Of 30 patients that received CY, 18(60%) and 27(90%)
achieved full (>95%) donor CD3+ and CD15+chimerism by
day +30, respectively vs. 1 (7%) and 12 (86%) in 16 patients
who underwent MRD transplants. Day +30 total T cell
recovery was signiﬁcantly faster in MRD than CY-treated
recipients (p¼0.015) due principally to more robust CD8+ T
cell recovery. CD4 T cell recovery remained incomplete in all
groups through day +100. Recovery of gd T cells did not differ
between groups. Regulatory T cells are virtually absent. NK
cells recover to normal numbers at day +28 in all groups.
Conclusions: Recipients of HAP, MUD andmMUD grafts who
received post-HSCT CY show similar engraftment kinetics as
those who receive MRD grafts with standard immunosup-
pression. T-cell engraftment appears to follow myeloid
engraftment in those who received post-transplant CYand is
generally earlier by day 30 than in MSD graft recipients,
although CD3+CD8+ recovery is greater in MRD recipients
than others. Taken together, HPC-Apheresis is a reasonable
alternative donor graft source when accompanied by post-
HSCT CY-based GvHD prophylaxis.29
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Background: Haploidentical stem cell transplantation
(HaploSCT) using post-transplant cyclophosphamide (PTCY)
has been performed primarily with non-myeloablative con-
ditioning. We are exploring a melphalan-based, myeloa-
blative yet reduced-intensity conditioning (RIC), in an
ongoing phase II clinical trial.
Methods: Outcomes of the ﬁrst 84 pts treated after 01/2009
are reported. 47(56%) pts were males. 74 (88%) pts had their
ﬁrst transplant, 10 (12%) as second transplant. The median
age was 46 years (range 19-67). 57 (67.9%) pts were protocol
